Newsfile Corp
18 May 2026, 13:50 UTC · 18w ago
Verdict
Headline leans bearish. We score BIIB −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
The CELIA trial for Biogen's BIIB080 Alzheimer's drug failed to achieve statistical significance on its primary endpoint.
So whatFailure of a primary endpoint in a major pipeline drug typically leads to significant valuation write-downs and loss of growth catalysts.
More negative than 99% of claims this week
Levi & Korsinsky LLP has commenced an investigation into Biogen Inc. for potential violations of federal securities laws.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 78% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is under investigation for possible securities fraud following a failed clinical trial and a sharp stock price decline.
More negative than 85% of ticker scores this week
The company is the subject of a fraud investigation on behalf of shareholders.
More negative than 85% of ticker scores this week
The company is being investigated by a law firm for potentially misleading investors.
More positive than 54% of ticker scores this week
Mentioned positively as a leader accounting for a significant portion of AI activity in corporate news analysis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
+17.3%
Price is moving against the score
$226.36 vs $192.95 close before publication (May 15) · not market-adjusted
BIIB chart →
